InflaRx (IFRX) Total Non-Current Liabilities (2016 - 2026)
InflaRx's (IFRX) quarterly Total Non-Current Liabilities came in at $694361.3 in Q2 2026, up 154.79% year-over-year from $272525.0 in Q2 2025, and down 2.55% quarter-over-quarter from $712532.2 in Q1 2026.
Analysis
InflaRx (IFRX) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
InflaRx has disclosed Total Non-Current Liabilities across 11 years of filings, most recently posting $694361.3 for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 154.79% year-over-year to $694361.3; the TTM figure through Jun 2026 stood at $694361.3 (up 154.79% YoY), while the FY2025 annual figure was $765842.5, up 64.4% from the prior year.
- Total Non-Current Liabilities came in at $694361.3 for Q2 2026 at InflaRx, down from $712532.2 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.3 million in Q2 2022 to a low of $272525.0 in Q2 2025.
- Average Total Non-Current Liabilities over 5 years is $805455.9, with a median of $835966.4 recorded in 2023.
- Year-over-year, Total Non-Current Liabilities surged 446.31% in 2022 and sank 60.34% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $1.0 million in 2022, then decreased by 19.42% to $842023.0 in 2023, then tumbled by 44.68% to $465846.7 in 2024, then soared by 69.38% to $789046.9 in 2025, then fell by 12.0% to $694361.3 in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $694361.3 in Q2 2026, $712532.2 in Q1 2026, and $789046.9 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 378.37 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | 694,361.26 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 694,361.26 |
| Mar 31, 2026 | 712,532.19 |
| Dec 31, 2025 | 789,046.90 |
| Sep 30, 2025 | 861,618.15 |
| Jun 30, 2025 | 272,524.95 |
| Mar 31, 2025 | 349,563.29 |
| Dec 31, 2024 | 465,846.68 |
| Sep 30, 2024 | 588,431.50 |
| Jun 30, 2024 | 687,131.81 |
| Mar 31, 2024 | 829,909.78 |
| Dec 31, 2023 | 842,023.04 |
| Sep 30, 2023 | 880,333.32 |
| Jun 30, 2023 | 927,150.52 |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | 1.04 Mn |
| Sep 30, 2022 | 1.13 Mn |
| Jun 30, 2022 | 1.29 Mn |
| Mar 31, 2022 | 1.13 Mn |
| Dec 31, 2021 | 1.26 Mn |
| Sep 30, 2021 | 1.40 Mn |